文献速递新发突发、热带与寄生虫病

非洲9国恶性疟原虫kelch 13基因突变监测(2014–2018年)

Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018.
PubMed 文献 · Emerg Infect Dis · 2021-01-01

该研究对2014–2018年9个撒哈拉以南非洲国家疗效研究入组患者的样本进行Sanger测序,检测恶性疟原虫kelch 13螺旋桨区突变。2,865份成功测序样本中,29份(1.0%)含11种非同义突变,83份(2.9%)含27种同义突变;肯尼亚2份样本携带S522C突变,但未发现已验证或候选的青蒿素耐药突变。

要点

  • 非洲9国青蒿素部分耐药相关kelch 13突变总体少见
  • 肯尼亚检出2份S522C突变样本,与虫体清除延迟相关
  • 未检出已验证或候选青蒿素耐药突变,需持续分子监测

核心结论

  • 2014–2018年9个撒哈拉以南非洲国家中,kelch 13非同义突变占1.0%、同义突变占2.9%,未发现已验证或候选青蒿素耐药突变。

研究设计与样本

  • 对2014–2018年9个撒哈拉以南非洲国家治疗疗效研究入组患者样本,采用Sanger测序检测恶性疟原虫kelch 13螺旋桨区突变。
  • 治疗前(入组当天)及治疗失败日成功测序样本共2,865份。

主要发现

  • 2,865份成功测序样本中,29份(1.0%)含11种独特非同义突变。
  • 83份(2.9%)样本含27种独特同义突变。
  • 肯尼亚2份样本携带S522C突变,该突变与虫体清除延迟相关。
  • 无样本含已验证或候选青蒿素耐药突变。

临床怎么用

  • 提示非洲部分地区的kelch 13突变以少见非同义/同义突变为主,S522C值得关注。
  • 支持在非洲疟疾流行区继续开展青蒿素耐药分子监测,并结合疗效研究解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The spread of drug resistance to antimalarial treatments poses a serious public health risk globally. To combat this risk, molecular surveillance of drug resistance is imperative. We report the prevalence of mutations in the Plasmodium falciparum kelch 13 propeller domain associated with partial artemisinin resistance, which we determined by using Sanger sequencing samples from patients enrolled in therapeutic efficacy studies from 9 sub-Saharan countries during 2014-2018. Of the 2,865 samples successfully sequenced before treatment (day of enrollment) and on the day of treatment failure, 29 (1.0%) samples contained 11 unique nonsynonymous mutations and 83 (2.9%) samples contained 27 unique synonymous mutations. Two samples from Kenya contained the S522C mutation, which has been associated with delayed parasite clearance; however, no samples contained validated or candidate artemisinin-resistance mutations.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schmedes SE, Patel D, Dhal S, et al. Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018. Emerg Infect Dis. 2021. PMID: 34152946. doi:10.3201/eid2707.203230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。